ESR1 and breast cancer: Among breast cancer subtypes, luminal B comprises ER-positive tumors with low progesterone-receptor expression, high proliferation, and poorer endocrine responses than luminal A [3, 4], with outcomes comparable to HER2-enriched subtype.